AU Patent

AU2024350159A1 — Compositions and methods comprising small nuclear rna (snrna) for treating dmd

Assigned to Regeneron Pharmaceuticals Inc · Expires 2026-04-02 · 0y expired

What this patent protects

SnRNA systems targeting DMA RNA sequences are disclosed herein.

USPTO Abstract

SnRNA systems targeting DMA RNA sequences are disclosed herein.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024350159A1
Jurisdiction
AU
Classification
—
Expires
2026-04-02
Drug substance claim
No
Drug product claim
No
Assignee
Regeneron Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.